Go to the list of all blogs
Alicia's Avatar
published in Blogs
May 01, 2026

Alignment Healthcare (ALHC) Shares Fall -11.18% After Q1 Earnings: What Stands Out to Me

Key Takeaways

  • Shares of ALHC plunged 11.18% to $20.02 from the previous close of $22.54.
  • The selloff followed first-quarter 2026 earnings, where revenue beat estimates at $1.235 billion but EPS missed at $0.05 versus $0.09 expected.
  • Trading volume surged above average, reflecting heightened investor reaction to the results.
  • Broader healthcare sector context showed mixed performance amid ongoing Medicare Advantage scrutiny.
  • Investors are watching Q2 guidance, membership growth trends, and the upcoming BofA Securities Health Care Conference presentation on May 13.

The Post-Earnings Selloff in ALHC

Alignment Healthcare, Inc. (ALHC), which operates a consumer-centric healthcare platform offering Medicare Advantage plans to seniors, experienced a sharp decline in Thursday's trading. The stock dropped 11.18% to $20.02 from the prior close of $22.54. In my view, the market's reaction stemmed largely from the earnings release, even as revenue showed impressive growth in the first quarter.

Breaking Down the Q1 Numbers

Alignment Healthcare reported its Q1 2026 results after Wednesday's market close, with revenue reaching $1.235 billion—a 33.3% increase year-over-year that beat analyst expectations. The company pointed to strong membership growth of 31% and advances in margin expansion via operational efficiencies and AI-driven workflows. That said, adjusted EPS of $0.05 fell short of the $0.09 consensus estimate. This miss prompted profit-taking and selling, which overshadowed the solid top-line results and the raised full-year adjusted EBITDA outlook of $138 million to $163 million. One thing that stands out is how revenue strength didn't fully offset the EPS disappointment in the short term.

Trading Activity and Broader Market Signals

Volume jumped notably, surpassing 5 million shares against an average daily volume of about 3 million, underscoring keen investor focus on the earnings. The stock's move stood apart from broader indices, which were mixed, and healthcare peers in Medicare Advantage displayed varied responses. On the technical side, ALHC broke below recent support around $21.50, fueling further downside amid post-earnings volatility. I also looked at this through Tickeron’s AI Screener to gauge how it stacks up against industry peers.

Insights from Tickeron's Trending AI Robots

In times like these, with earnings-driven volatility in stocks like ALHC, I find value in exploring Tickeron’s Trending AI Robots. This page highlights the platform's top-performing AI-driven trading bots based on current market conditions. Tickeron provides hundreds of these bots, each using strategies such as trend-following, mean reversion, or momentum across different timeframes and metrics. They scan and trade thousands of tickers, including healthcare names, and adjust to events like earnings releases. From what I see, the curated top performers offer useful, data-backed ideas for aligning with various trading approaches.

Looking Ahead for ALHC

The company reaffirmed its Q2 revenue guidance of $1.3 billion to $1.32 billion and adjusted EBITDA of $50 million to $60 million, with full-year membership growth remaining on track. Executives are set to present at the BofA Securities Health Care Conference on May 13, potentially shedding more light on strategic plans. Analysts hold a consensus "Buy" rating, with price targets near $24-$25, based on Medicare Advantage growth potential. I'm watching key risks closely, including regulatory shifts in reimbursements, competition, and cost control execution against sector challenges.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ALHC

Contributor

Alicia's AvatarAlicia|Beginner

ALHC in upward trend: price expected to rise as it breaks its lower Bollinger Band on July 31, 2026

ALHC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 36 cases where ALHC's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ALHC's RSI Indicator exited the oversold zone, of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 20 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Moving Average Convergence Divergence (MACD) for ALHC just turned positive on August 21, 2026. Looking at past instances where ALHC's MACD turned positive, the stock continued to rise in of 40 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ALHC advanced for three days, in of 308 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on July 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALHC as a result. In of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

ALHC moved below its 50-day moving average on July 27, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ALHC crossed bearishly below the 50-day moving average on July 31, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

The 50-day moving average for ALHC moved below the 200-day moving average on August 06, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALHC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for ALHC entered a downward trend on August 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ALHC's P/B Ratio (10.299) is very high in comparison to the industry average of (3.666). P/E Ratio (69.289) is within average values for comparable stocks, (149.731). ALHC's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.216). ALHC's Dividend Yield (0.000) is considerably lower than the industry average of (0.020). P/S Ratio (0.588) is also within normal values, averaging (0.569).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ALHC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALHC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.

Notable companies

The most notable companies in this group are Unitedhealth Group (NYSE:UNH), CVS HEALTH Corp (NYSE:CVS), Elevance Health (NYSE:ELV), Cigna Group (The) (NYSE:CI), Humana (NYSE:HUM), Centene Corp (NYSE:CNC).

Industry description

Managed healthcare industry focuses on providing health/medical and disability insurance plans, generally intended to reduce the cost of for-profit health care. The insurance products might be provided through employer-paid (fully or partly) insurance and benefit programs, or through Medicare/Medicaid. Some of the largest providers of managed health care include Aetna, Humana Inc., and Cigna, and UnitedHealthcare.

Market Cap

The average market capitalization across the Managed Health Care Industry is 66.74B. The market cap for tickers in the group ranges from 1.01M to 350.16B. UNH holds the highest valuation in this group at 350.16B. The lowest valued company is IHGP at 1.01M.

High and low price notable news

The average weekly price growth across all stocks in the Managed Health Care Industry was -4%. For the same Industry, the average monthly price growth was -9%, and the average quarterly price growth was 45%. ELV experienced the highest price growth at 0%, while CLOV experienced the biggest fall at -10%.

Volume

The average weekly volume growth across all stocks in the Managed Health Care Industry was -6%. For the same stocks of the Industry, the average monthly volume growth was -15% and the average quarterly volume growth was -28%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 39
P/E Growth Rating: 48
Price Growth Rating: 48
SMR Rating: 79
Profit Risk Rating: 89
Seasonality Score: 12 (-100 ... +100)
View a ticker or compare two or three
ALHC
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Industry ManagedHealthCare

Profile
Details
Industry
N/A
Address
1100 W. Town and Country Road
Phone
+1 844 310-2247
Employees
1849
Web
https://www.alignmenthealth.com
Interact to see
Advertisement
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.
Liberty Broadband Corporation (LBRDA) has experienced pronounced swings in recent weeks, touching multiyear lows before staging a sharp recovery. The stock continues to trade within a wide 52-week range, closely tied to the value of its Charter Communications stake and investor expectations around the proposed merger.
Apollo Global Management (APO), a leading alternative asset manager, reports Q4 and full-year 2025 results on February 9, 2026, before the market opens. The firm has delivered a year of strong growth, with AUM expanding on record inflows exceeding $200 billion and origination surpassing $300 billion.
Arm Holdings (ARM) shares have demonstrated resilience in recent sessions, rebounding after an initial earnings-related pullback and stabilizing near technical support levels. While smartphone-related headwinds tied to memory shortages pressured sentiment, momentum in AI-driven data center royalties helped restore confidence.
Shell plc (SHEL) reported Q4 2025 adjusted earnings of $3.3 billion, below expectations due to weaker oil prices and non-cash tax charges. Full-year adjusted earnings reached $18.5 billion, supported by strong LNG and upstream operations. A 4% dividend increase to $0.372 per share and a new $3.5 billion buyback program reinforce capital return commitments.
Linde (LIN) reported Q4 2025 adjusted EPS of $4.20, topping estimates, with full-year revenue reaching $34 billion. 2026 EPS guidance of $17.40–$17.90 implies 6–9% growth, supported by a record $10 billion project backlog.
ConocoPhillips (COP) reported Q4 2025 adjusted EPS of $1.02, missing estimates due to weaker oil prices. Full-year adjusted earnings totaled $7.7 billion, with $19.9 billion in operating cash flow. Shares have gained more than 10% in recent weeks, supported by analyst upgrades and sector momentum.
Intercontinental Exchange (ICE) has navigated recent market volatility while remaining within its 52-week range. Broader weakness in financial data and exchange operators has created short-term pressure, but ICE’s diversified business model continues to provide stability.
Verisk Analytics (VRSK) delivered Q4 2025 revenue of $779 million, up 5.9% year over year, with adjusted EPS of $1.82, beating expectations. Booz Allen Hamilton (BAH) reported Q3 FY2026 revenue of $2.62 billion, down 10.2% year over year, but adjusted diluted EPS climbed 14% to $1.77, well above estimates.
(OMC) Omnicom’s fourth-quarter report, released February 18, 2026, marked its first earnings update incorporating results from Interpublic Group (IPG), acquired on November 26, 2025. The combination created the world’s largest marketing services firm by revenue, a significant milestone as the advertising industry consolidates and adapts to digital transformation.
Copart (CPRT) is set to report fiscal Q2 2026 earnings on February 19, 2026, after market close. Consensus calls for EPS of $0.39–$0.40 and revenue of $1.15–$1.18 billion. Global Payments (GPN) posted Q4 2025 adjusted EPS of $3.18, in line with expectations, and adjusted net revenue of $2.32 billion, up 6% in constant currency (excluding dispositions). Thomson Reuters (TRI) delivered Q4 2025 adjusted EPS of $1.07 and revenue of $2.01 billion, up 5% year over year, supported by recurring subscription growth.
Unilever PLC (UL) leads year-to-date performance with a 12.61% gain, ahead of Diageo plc (DEO) at 9.90% and Keurig Dr Pepper Inc. (KDP) at 4.27%. DEO offers the highest dividend yield at 4.35%, compared with KDP (3.16%) and UL (2.97%). All three stocks carry low betas—DEO (0.18), UL (0.24), and KDP (0.35)—highlighting their defensive characteristics.
Q1 Fiscal 2026 Results: Revenue of $333M and adjusted EBITDA of $50M (15% margin), exceeding analyst expectations. FY2026 Guidance Raised: Adjusted EBITDA now projected at $225M, with revenue reaffirmed near $1.5B. EV Backlog Growth: 855 electric buses worth $277M, highlighting robust demand supported by EPA clean bus funding.
IBM fell over 10% today mainly because a new AI tool from Anthropic is seen as a direct threat to IBM’s lucrative COBOL modernization and consulting business, triggering worries that key legacy‑modernization revenue will be automated away.
Today’s drop is mainly about competitive positioning and future growth expectations, not an immediate collapse of current Wegovy/Ozempic sales, but it signals that Novo may not have the strongest next‑wave obesity drug versus Eli Lilly, which is why the stock sold off so sharply.
RNG (RingCentral) dropped over 12% today mainly as a sharp pullback after a very steep recent run‑up driven by upbeat Q4 results, guidance, and capital‑return news, with profit‑taking amplified by valuation concerns and a weak broader tech tap
Fundamentally, the latest public guidance is still for rapid growth and profitability, but today’s drop reflects a reset of sentiment and valuation rather than a brand‑new deterioration in those targets. For investors, the key question is whether the current price appropriately reflects execution risk, competition in diagnostics, and macro volatility after the guidance‑driven rally and subsequent reversal.
TNC (Tennant Company) is down more than 25% today because it reported a very large earnings and revenue miss for Q4 2025, blamed on serious ERP rollout problems and weaker demand, and guided to a slower‑than‑hoped recovery in 2026.
XMTR (Xometry) is down more than 21% today because, despite reporting record growth and an earnings beat, the company announced a CEO transition and investors used the news to take profits after a big prior run‑up, with heavy short interest amplifying the drop.